17,261 trials
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 5.9; 4.5 months
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I) — 100; 25; NA…
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Depression · Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 3.47; 4.09; 16.93; 14.64 units on a scale
Hepatitis C
Primary: Percentage of HCV GT3-infected Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) — 90.5; 95.2; 86.4; 90.9 Percentage of participants
Hyperkalemia · Chronic Kidney Disease · Kidney Dysfunction
Primary: Difference in the Exponential Rate of Change in Serum Potassium (S-K) Levels Versus Placebo During the Initial 48 Hours of Study Drug Treatment — 0; -0.00035; -0.00169…
Pregnancy
Primary: Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD). — 35; 11 Participants
Breast Cancer
Primary: Response Rate of Patients Who Receive Pre-operative or Palliative Concurrent Radiation w/ Capecitabine to the Breast & at Risk or Involved Regional Lymph Nodes Basins…
Ocular Melanoma
Primary: 4-month Progression Free Survival (PFS) Rate — 0.059; 0.118 proportion of participants
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 25/26 — 41; 92.3 ug/L — p=0.60
Rheumatoid Arthritis
Primary: Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 19; 30; 33; 40 Participants — p== 0.033
Exudative Macular Degeneration
Primary: Change From Baseline Visual Acuity at 6 Months — 3.8 number of letters
Viral Upper Respiratory Tract Infection
Primary: Total Symptom Scores — 22.5; 34.2; 36.2; 33.5 units on a scale
Bronchopulmonary Dysplasia
Primary: Incidence of Bronchopulmonary Dysplasia (BPD) — 76; 84 percentage w/ BPD — p=0.20
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants